JP2023507848A - 癌の治療のための療法 - Google Patents

癌の治療のための療法 Download PDF

Info

Publication number
JP2023507848A
JP2023507848A JP2022538737A JP2022538737A JP2023507848A JP 2023507848 A JP2023507848 A JP 2023507848A JP 2022538737 A JP2022538737 A JP 2022538737A JP 2022538737 A JP2022538737 A JP 2022538737A JP 2023507848 A JP2023507848 A JP 2023507848A
Authority
JP
Japan
Prior art keywords
cancer
lag
domain
molecule
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507848A5 (cg-RX-API-DMAC7.html
Inventor
ブラッドレイ ジェームズ スムラウ
モット-モース ロス ラ
ジョン マーク ウィギントン
エツィオ ボンビニ
ポール エー. ムーア
スコット ケーニヒ
シャオユ ジャン
Original Assignee
マクロジェニクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェニクス,インコーポレーテッド filed Critical マクロジェニクス,インコーポレーテッド
Publication of JP2023507848A publication Critical patent/JP2023507848A/ja
Publication of JP2023507848A5 publication Critical patent/JP2023507848A5/ja
Priority to JP2025154757A priority Critical patent/JP2026001028A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022538737A 2019-12-23 2020-12-18 癌の治療のための療法 Pending JP2023507848A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025154757A JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962952878P 2019-12-23 2019-12-23
US201962952859P 2019-12-23 2019-12-23
US62/952,878 2019-12-23
US62/952,859 2019-12-23
US202063019857P 2020-05-04 2020-05-04
US63/019,857 2020-05-04
US202063021556P 2020-05-07 2020-05-07
US63/021,556 2020-05-07
US202063031453P 2020-05-28 2020-05-28
US63/031,453 2020-05-28
US202063123581P 2020-12-10 2020-12-10
US63/123,581 2020-12-10
PCT/US2020/065873 WO2021133653A1 (en) 2019-12-23 2020-12-18 Therapy for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025154757A Division JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Publications (2)

Publication Number Publication Date
JP2023507848A true JP2023507848A (ja) 2023-02-27
JP2023507848A5 JP2023507848A5 (cg-RX-API-DMAC7.html) 2023-12-21

Family

ID=76575359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538737A Pending JP2023507848A (ja) 2019-12-23 2020-12-18 癌の治療のための療法
JP2025154757A Pending JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025154757A Pending JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Country Status (13)

Country Link
US (1) US20230056230A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081248A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023507848A (cg-RX-API-DMAC7.html)
KR (1) KR20220119694A (cg-RX-API-DMAC7.html)
CN (1) CN114901306A (cg-RX-API-DMAC7.html)
AU (1) AU2020412595A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012437A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165839A1 (cg-RX-API-DMAC7.html)
IL (1) IL294207A (cg-RX-API-DMAC7.html)
MX (1) MX2022007790A (cg-RX-API-DMAC7.html)
TW (1) TW202138387A (cg-RX-API-DMAC7.html)
WO (1) WO2021133653A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202206743B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7745556B2 (ja) * 2020-02-21 2025-09-29 マクロジェニクス,インコーポレーテッド Cd137結合分子及びその使用
CA3196496A1 (en) * 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
KR20240028452A (ko) * 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
KR20240038005A (ko) * 2021-07-16 2024-03-22 마크로제닉스, 인크. B7-h3 항체의 약학적 조성물 및 그것의 용도
IL309120A (en) * 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for the treatment of cancer
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
TW202328198A (zh) * 2021-10-21 2023-07-16 大陸商杭州阿諾生物醫藥科技有限公司 一種融合多肽及其用途
US20240117051A1 (en) * 2022-09-09 2024-04-11 Akeso Biopharma, Inc. Therapeutic combination and use thereof
TW202436339A (zh) * 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024163009A1 (en) * 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017035086A (ja) * 2010-03-04 2017-02-16 マクロジェニクス,インコーポレーテッド B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
JP2017526632A (ja) * 2014-06-26 2017-09-14 マクロジェニクス,インコーポレーテッド Pd‐1及びlag‐3との免疫反応性を有する共有結合ダイアボディ並びにその使用方法
JP2018523686A (ja) * 2015-08-17 2018-08-23 マクロジェニクス,インコーポレーテッド B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用
JP2018524394A (ja) * 2015-07-30 2018-08-30 マクロジェニクス,インコーポレーテッド Pd‐1結合分子及びその使用方法
WO2018178122A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
JP2019520308A (ja) * 2016-04-15 2019-07-18 マクロジェニクス,インコーポレーテッド 新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
WO2019152642A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
JP7085709B2 (ja) * 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
JP7301002B2 (ja) * 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
US20210115138A1 (en) * 2018-03-20 2021-04-22 WuXi Biologics Ireland Limited Novel bispecific pd-1/lag-3 antibody molecules

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017035086A (ja) * 2010-03-04 2017-02-16 マクロジェニクス,インコーポレーテッド B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
JP2017526632A (ja) * 2014-06-26 2017-09-14 マクロジェニクス,インコーポレーテッド Pd‐1及びlag‐3との免疫反応性を有する共有結合ダイアボディ並びにその使用方法
JP2018524394A (ja) * 2015-07-30 2018-08-30 マクロジェニクス,インコーポレーテッド Pd‐1結合分子及びその使用方法
JP2018523686A (ja) * 2015-08-17 2018-08-23 マクロジェニクス,インコーポレーテッド B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用
JP2019520308A (ja) * 2016-04-15 2019-07-18 マクロジェニクス,インコーポレーテッド 新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法
WO2018178122A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
WO2019152642A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 5, Supp.2, JPN6024048858, 2017, pages 87 - 337, ISSN: 0005747370 *
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 5, Supp.2, JPN6024048859, 2017, pages 87 - 244, ISSN: 0005747369 *
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 7, Supp.1, JPN6024048860, November 2019 (2019-11-01), pages 282 - 375, ISSN: 0005747368 *

Also Published As

Publication number Publication date
IL294207A (en) 2022-08-01
CN114901306A (zh) 2022-08-12
KR20220119694A (ko) 2022-08-30
EP4081248A1 (en) 2022-11-02
JP2026001028A (ja) 2026-01-06
CA3165839A1 (en) 2021-07-01
BR112022012437A2 (pt) 2022-09-20
US20230056230A1 (en) 2023-02-23
MX2022007790A (es) 2022-10-18
WO2021133653A1 (en) 2021-07-01
ZA202206743B (en) 2023-05-31
AU2020412595A1 (en) 2022-07-14
EP4081248A4 (en) 2024-01-10
TW202138387A (zh) 2021-10-16
WO2021133653A8 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
JP7132232B2 (ja) Cd137及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP2026001028A (ja) 癌の治療のための療法
AU2016274485B2 (en) LAG-3-binding molecules and methods of use thereof
JP2022058802A (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
KR20180034588A (ko) Pd-1-결합 분자 및 그것의 사용 방법
AU2016276706A1 (en) Combination therapy for the treatment of cancer
EP3250601A1 (en) Multivalent molecules comprising dr5-binding domains
BR112020016485A2 (pt) Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença
US12435155B2 (en) CD137 binding molecules and uses thereof
AU2018385409A1 (en) Bispecific CD 16-binding molecules and their use in the treatment of disease
JP2023536086A (ja) Pd‐1×ctla‐4二重特異性分子の使用のための方法
EA046873B1 (ru) Cd137-связывающие молекулы и варианты их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918